Aclaris Therapeutics Share Price Today
(NASDAQ: ACRS)

Name: Aclaris Therapeutics Share Price Today (NASDAQ: ACRS) - Aclaris Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Aclaris Therapeutics share price is $1.85 & ₹160.89 as on 6 Mar 2025, 2.30 'hrs' IST

$1.85

▲

-0.08

(-4.15%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Aclaris Therapeutics share price in Dollar and Rupees. Guide to invest in Aclaris Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Aclaris Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Aclaris Therapeutics share price movements

Today's Low: $1.84
Today's High: $1.96
$1.85
0.54%
Downside
Day's Volatility :6.12%
Upside
5.61%
52 Weeks Low: $0.95
52 Weeks High: $5.17
$1.85
48.57%
Downside
52 Weeks Volatility :81.6%
Upside
64.22%

Aclaris Therapeutics (ACRS) Returns

Period	Aclaris Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-51.44%	3.7%	0.0%
6 Months	56.78%	-2.8%	0.0%
1 Year	28.47%	2.5%	0.0%
3 Years	-88.87%	12.9%	-11.6%

Aclaris Therapeutics (ACRS) Key Statistics

in dollars & INR

Previous Close	$1.93
Open	$1.92
Today's High	$1.96
Today's Low	$1.84
Market Capitalization	$208.7M
Today's Volume	$438.6K
52 Week High	$5.17
52 Week Low	$0.9515
Revenue TTM	$18.7M
EBITDA	$-52.2M
Earnings Per Share (EPS)	$-1.68
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-84.46%

How to invest in Aclaris Therapeutics Stock (ACRS) from India?

It is very easy for Indian residents to invest directly in Aclaris Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Aclaris Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Aclaris Therapeutics or ACRS on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Aclaris Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Aclaris Therapeutics shares which would translate to 0.470 fractional shares of Aclaris Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Aclaris Therapeutics, in just a few clicks!

Returns in Aclaris Therapeutics (ACRS) for Indian investors in Rupees

The Aclaris Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Aclaris Therapeutics investment value today

Current value as on today

₹1,33,421

Returns

₹33,421

(+33.42%)

Returns from Aclaris Therapeutics Stock

₹28,472 (+28.47%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Aclaris Therapeutics (ACRS)

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Aclaris Therapeutics Stock from India on INDmoney has increased by 5% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Aclaris Therapeutics

BML Capital Management LLC
13.32%
Adage Capital Partners Gp LLC
9.00%
Vivo Capital, LLC
8.31%
Rock Springs Capital Management LP
5.80%
RA Capital Management, LLC
4.36%
Vanguard Group Inc
4.04%

Analyst Recommendation on Aclaris Therapeutics

Hold

40%Buy

60%Hold

0%Sell

Based on 15 Wall street analysts offering stock ratings for Aclaris Therapeutics(by analysts ranked 0 to 5 stars)

Based on 15 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Aclaris Therapeutics Stock (ACRS)

What analysts predicted

Upside of 494.59%

Target:

$11.00

Current:

$1.85

Insights on Aclaris Therapeutics Stock (Ticker Symbol: ACRS)

Price Movement
In the last 3 months, ACRS stock has moved down by -53.0%
Increasing Revenue
Revenue is up for the last 4 quarters, 2.39M → 9.21M (in $), with an average increase of 34.2% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -7.58M → -96.55M (in $), with an average decrease of 1172.8% per quarter
ACRS vs TMO (3 yr)
In the last 3 years, Aclaris Therapeutics Inc has experienced a drawdown of -88.3%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 84.1%

ACRS Aclaris Therapeutics Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$4.2M	↓ 58.11%
Net Income	$-142.9M	↑ 7.62%
Net Profit Margin	-3.4K%	↓ 2064.06%

	FY20	Y/Y Change
Revenue	$6.5M	↑ 53.35%
Net Income	$-51.2M	↓ 64.19%
Net Profit Margin	-789.17%	↑ 2590.3%

	FY21	Y/Y Change
Revenue	$6.8M	↑ 4.3%
Net Income	$-114.3M	↑ 123.41%
Net Profit Margin	-1.7K%	↓ 901.13%

	FY22	Y/Y Change
Revenue	$29.8M	↑ 340.05%
Net Income	$-88.7M	↓ 22.42%
Net Profit Margin	-298.0%	↑ 1392.3%

	FY23	Y/Y Change
Revenue	$31.2M	↑ 5.03%
Net Income	$-88.5M	↓ 0.2%
Net Profit Margin	-283.15%	↑ 14.85%

	FY24	Y/Y Change
Revenue	$18.7M	↓ 40.09%
Net Income	$-132.1M	↑ 49.26%
Net Profit Margin	-705.48%	↓ 422.33%

	Q3 FY23	Q/Q Change
Revenue	$9.3M	↑ 396.63%
Net Income	$-29.3M	↓ 1.04%
Net Profit Margin	-315.24%	↑ 1266.84%

	Q4 FY23	Q/Q Change
Revenue	$17.6M	↑ 89.29%
Net Income	$-1.5M	↓ 94.9%
Net Profit Margin	-8.49%	↑ 306.75%

	Q1 FY24	Q/Q Change
Revenue	$2.4M	↓ 86.35%
Net Income	$-16.9M	↑ 1036.22%
Net Profit Margin	-706.46%	↓ 697.97%

	Q2 FY24	Q/Q Change
Revenue	$2.8M	↑ 15.35%
Net Income	$-11.0M	↓ 35.15%
Net Profit Margin	-397.18%	↑ 309.28%

	Q3 FY24	Q/Q Change
Revenue	$4.3M	↑ 57.12%
Net Income	$-7.6M	↓ 30.95%
Net Profit Margin	-174.55%	↑ 222.63%

	Q4 FY24	Q/Q Change
Revenue	$9.2M	↑ 111.94%
Net Income	$-96.6M	↑ 1172.77%
Net Profit Margin	-1.0K%	↓ 873.67%

	FY19	Y/Y Change
Profit	$172.0K	↓ 94.69%

	FY20	Y/Y Change
Profit	$1.3M	↑ 684.3%

	FY21	Y/Y Change
Profit	$2.0M	↑ 51.82%

	FY22	Y/Y Change
Profit	$17.8M	↑ 768.75%

	FY23	Y/Y Change
Profit	$13.2M	↓ 25.99%

	FY24	Y/Y Change
Profit	$15.9M	↑ 20.96%

	Q3 FY23	Q/Q Change
Profit	$8.4M	↑ 2944.77%

	Q4 FY23	Q/Q Change
Profit	$11.1M	↑ 32.11%

	Q1 FY24	Q/Q Change
Profit	$558.0K	↓ 94.99%

	Q2 FY24	Q/Q Change
Profit	$857.0K	↑ 53.58%

	Q3 FY24	Q/Q Change
Profit	$1.9M	↑ 126.14%

	Q4 FY24	Q/Q Change
Profit	$-90.0K	↓ 104.64%

	FY19	Y/Y Change
Operating Cash Flow	$-96.4M	↓ 4.33%
Investing Cash Flow	$105.7M	↑ 1028.21%
Financing Cash Flow	$-30.3M	↓ 123.64%

	FY20	Y/Y Change
Operating Cash Flow	$-38.6M	↓ 59.94%
Investing Cash Flow	$6.4M	↓ 93.96%
Financing Cash Flow	$18.4M	↓ 160.6%

	FY21	Y/Y Change
Operating Cash Flow	$-52.1M	↑ 34.95%
Investing Cash Flow	$-167.6M	↓ 2724.58%
Financing Cash Flow	$225.1M	↑ 1124.97%

	FY22	Y/Y Change
Operating Cash Flow	$-67.6M	↑ 29.6%
Investing Cash Flow	$12.6M	↓ 107.53%
Financing Cash Flow	$72.9M	↓ 67.62%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$-24.6M	↑ 18.9%
Investing Cash Flow	$32.5M	↓ 265.47%
Financing Cash Flow	$-87.0K	↓ 100.33%

Aclaris Therapeutics Technicals Summary

Sell

Neutral

Buy

Aclaris Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Aclaris Therapeutics (ACRS) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Aclaris Therapeutics Inc	-26.29%	56.78%	28.47%	-88.87%	86.81%
Agilent Technologies Inc.	-13.96%	-8.56%	-13.48%	-2.94%	78.81%
Idexx Laboratories, Inc.	-5.98%	-6.81%	-21.57%	-15.48%	80.06%
Thermo Fisher Scientific, Inc.	-9.71%	-13.63%	-11.38%	-1.97%	77.48%
Danaher Corp.	-2.07%	-20.46%	-16.74%	-19.95%	48.71%
Iqvia Holdings Inc.	-7.09%	-25.1%	-26.53%	-14.22%	49.88%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Aclaris Therapeutics Inc	NA	NA	-0.13	-0.6	-0.84	-0.16	NA	1.44
Agilent Technologies Inc.	29.02	29.02	2.0	5.57	0.21	0.08	0.01	21.13
Idexx Laboratories, Inc.	41.39	41.39	4.36	11.97	0.58	0.23	NA	19.55
Thermo Fisher Scientific, Inc.	31.65	31.65	2.02	23.33	0.13	0.05	0.0	130.22
Danaher Corp.	38.92	38.92	2.05	7.65	0.08	0.04	0.01	68.9
Iqvia Holdings Inc.	24.81	24.81	0.98	11.89	0.23	0.05	NA	34.45

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Aclaris Therapeutics Inc	Hold	$208.7M	86.81%	NA	0.0%
Agilent Technologies Inc.	Buy	$36.1B	78.81%	29.02	19.27%
Idexx Laboratories, Inc.	Buy	$35.9B	80.06%	41.39	22.78%
Thermo Fisher Scientific, Inc.	Buy	$194.9B	77.48%	31.65	14.77%
Danaher Corp.	Buy	$147.2B	48.71%	38.92	16.33%
Iqvia Holdings Inc.	Buy	$32.8B	49.88%	24.81	8.91%

About Aclaris Therapeutics

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Organization	Aclaris Therapeutics
Employees	61
CEO	Dr. Neal S. Walker D.O., M.D.
Industry	Health Technology

Management People of Aclaris Therapeutics

Name	Title
Dr. Neal S. Walker D.O., M.D.	Co-Founder, CEO & Chairman
Dr. Hugh M. Davis Ph.D.	President, COO & Director
Mr. Kevin Balthaser	Chief Financial Officer
Dr. Joseph Monahan Ph.D.	Chief Scientific Officer
Mr. Matthew Rothman J.D.	General Counsel & Corporate Secretary
Dr. Jon Jacobsen Ph.D.	Senior Vice President of Chemistry
Mr. James Loerop	Chief Business Officer
Mr. Steve Tucker	Senior Vice President of Project Leadership
Mr. Ajay Aggarwal M.B.A., M.D.	Senior Vice President of Clinical Development
Dr. Steven Knapp M.S. Pharm.D.	Executive Vice President, Regulatory Affairs & Quality Assurance

Important FAQs about investing in ACRS Stock from India :

What is Aclaris Therapeutics share price today?

Aclaris Therapeutics share price today stands at $1.85, Open: $1.92 ; Previous Close: $1.93 ; High: $1.96 ; Low: $1.84 ; 52 Week High: $5.17 ; 52 Week Low: $0.95.

The stock opens at $1.92, after a previous close of $1.93. The stock reached a daily high of $1.96 and a low of $1.84, with a 52-week high of $5.17 and a 52-week low of $0.95.

Can Indians buy Aclaris Therapeutics shares?

Yes, Indians can invest in the Aclaris Therapeutics (ACRS) from India.

With INDmoney, you can buy Aclaris Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Aclaris Therapeutics at zero transaction cost.

How can I buy Aclaris Therapeutics shares from India?

It is very easy to buy Aclaris Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Aclaris Therapeutics (ACRS) be purchased?

Yes, you can buy fractional shares of Aclaris Therapeutics with INDmoney app.

What are the documents required to start investing in Aclaris Therapeutics stocks?

To start investing in Aclaris Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.